Brief: Creative Medical Technology Announces Progress In Developing A Reproducible Clinical Grade Of The Company's Immcelz® Product
20/04/2022 14:38
April 20 (Reuters) - Creative Medical Technology Holdings
Inc CELZ.O :
* CREATIVE MEDICAL TECHNOLOGY ANNOUNCES PROGRESS IN
DEVELOPING A
REPRODUCIBLE CLINICAL GRADE OF THE COMPANY'S IMMCELZ® PRODUCT
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS- INITIAL EXPERIMENTS
SHOW
EXPEDITIOUS POTENTIAL FOR HIGH-VOLUME PRODUCTION OF IMMCELZ WITH
CONSISTENT POTENCY
Source text for Eikon: ID:nPn4wn2dGa
Further company coverage: CELZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM